Cipher Pharmaceuticals
Open
–
Prev. Close
–
High
–
Low
–
Market Snapshot
0.14
$68.82M
5
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario and currently employs 61 full-time employees. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
emptyResult
Cipher Pharmaceuticals, Inc. engages in a diversified portfolio of commercial and early to late-stage products. The company is headquartered in Mississauga, Ontario and currently employs 61 full-time employees. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. The company delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Recently from Cashu
Cipher Pharmaceuticals Launches Innovative Dermatology Treatment for Acne and Psoriasis
Cipher Pharmaceuticals Advances in Dermatology with New Product Launch Cipher Pharmaceuticals, a Canadian specialty pharmaceutical company, is making significant strides in the dermatology sector with…
Cipher Pharmaceuticals: Key Updates and Insights on Recent Developments and Market Trends
Please provide the text you'd like me to summarize, and I'll be happy to help.
Cipher Pharmaceuticals: Key Developments and Market Insights
Please provide the content you would like me to summarize, and I'll assist you accordingly.
Cipher Pharmaceuticals: Key Updates and Future Outlook for Stock Performance
Please provide the content you’d like summarized, and I will be happy to assist!